Tumour escape from immune surveillance through dendritic cell inactivation
- 28 February 2002
- journal article
- review article
- Published by Elsevier BV in Seminars in Cancer Biology
- Vol. 12 (1), 33-42
- https://doi.org/10.1006/scbi.2001.0400
Abstract
No abstract availableKeywords
This publication has 82 references indexed in Scilit:
- Innate and adaptive immunity to tumors: IL-12 is required for optimal responsesEuropean Journal of Immunology, 2000
- Consequences of Cell DeathThe Journal of Experimental Medicine, 2000
- Dendritic Cells Infiltrating Tumors Cotransduced with Granulocyte/Macrophage Colony-Stimulating Factor (Gm-Csf) and Cd40 Ligand Genes Take up and Present Endogenous Tumor-Associated Antigens, and Prime Naive Mice for a Cytotoxic T Lymphocyte ResponseThe Journal of Experimental Medicine, 1999
- Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF.JCI Insight, 1998
- The host—tumor immune conflict: from immunosuppression to resistance and destructionImmunology Today, 1997
- Cancer Tumor antigensCurrent Opinion in Immunology, 1997
- Effect of interleukin‐10 on dendritic cell maturation and functionEuropean Journal of Immunology, 1997
- Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cellsNature Medicine, 1996
- Spontaneous apoptosis of dendritic cells is efficiently inhibited by TRAP (CD40‐ligand) and TNF‐α, but strongly enhanced by interleukin‐10European Journal of Immunology, 1995
- Role of Bone Marrow-Derived Cells in Presenting MHC Class I-Restricted Tumor AntigensScience, 1994